Century Therapeutics’ (IPSC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC) in a report published on Wednesday morning,Benzinga reports. They currently have a $5.00 price target on the stock.

Several other equities analysts have also issued reports on IPSC. Chardan Capital lowered their price target on Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Piper Sandler lowered their price objective on Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a research report on Monday, December 30th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $10.00.

Century Therapeutics Trading Down 1.1 %

IPSC opened at $0.90 on Wednesday. Century Therapeutics has a 1-year low of $0.86 and a 1-year high of $5.51. The business has a 50 day moving average of $1.17 and a 200-day moving average of $1.55. The stock has a market capitalization of $76.53 million, a price-to-earnings ratio of -0.49 and a beta of 1.76.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.08. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. The company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.47 million. During the same period last year, the business posted ($0.55) EPS. Equities analysts predict that Century Therapeutics will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently modified their holdings of IPSC. Renaissance Technologies LLC lifted its position in shares of Century Therapeutics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after buying an additional 9,500 shares during the period. SG Americas Securities LLC bought a new position in shares of Century Therapeutics during the third quarter valued at $27,000. Rhumbline Advisers boosted its stake in shares of Century Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock valued at $134,000 after purchasing an additional 18,828 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Century Therapeutics by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company’s stock worth $1,656,000 after purchasing an additional 32,614 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after purchasing an additional 44,155 shares in the last quarter. 50.20% of the stock is currently owned by institutional investors.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.